Artelo Biosciences, Inc. - Common Stock (ARTL)

A new wave of market-moving developments across biotech, defense technology, and emerging growth companies is putting Apellis Pharmaceuticals, Inc. (NASDAQ: APLS), Virtuix Holdings, Inc. (NASDAQ: VTIX) , PMGC Holdings Inc. (NASDAQ: ELAB) , and Artelo Biosciences, Inc. (NASDAQ: ARTL) firmly on investor watchlists. Biotech M&A activity, defense-driven VR adoption, strategic capital deployment, and fresh funding catalysts are all contributing to rising investor interest across multiple high-growth sectors.

Synergy CHC Corp. (NASDAQ: SNYR), a rising consumer staple health company, has announced a wave of major expansion throughout North American for its FOCUSfactor® supplements and functional beverage brands, across mass, grocery, convenience, and wholesale channels. Functional Beverage Momentum

SOLANA BEACH, CA / ACCESSWIRE / May 13, 2022 / Artelo Biosciences, Inc. "Artelo" or the "Company") (NASDAQ:ARTL), a clinical stage pharmaceutical company developing therapeutics that modulate lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory D. Gorgas, Chief Executive Officer of Artelo has been invited to present at the Spring Into Action - Best Ideas Virtual Investor Conference, which is being held

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies will be presenting via virtual webcast to a global investor audience. The Spring into Action: VIRTUAL begins on Monday, May 16th, 2022, with a Biotech Discovery Day. Company presentations begin at 1:30 PM Eastern Time. Presentations will be